230 related articles for article (PubMed ID: 32546576)
1. Lineage Reversion Drives WNT Independence in Intestinal Cancer.
Han T; Goswami S; Hu Y; Tang F; Zafra MP; Murphy C; Cao Z; Poirier JT; Khurana E; Elemento O; Hechtman JF; Ganesh K; Yaeger R; Dow LE
Cancer Discov; 2020 Oct; 10(10):1590-1609. PubMed ID: 32546576
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.
Trobridge P; Knoblaugh S; Washington MK; Munoz NM; Tsuchiya KD; Rojas A; Song X; Ulrich CM; Sasazuki T; Shirasawa S; Grady WM
Gastroenterology; 2009 May; 136(5):1680-8.e7. PubMed ID: 19208363
[TBL] [Abstract][Full Text] [Related]
3. Combined Mutation of
Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
[TBL] [Abstract][Full Text] [Related]
4. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy.
Hinze L; Labrosse R; Degar J; Han T; Schatoff EM; Schreek S; Karim S; McGuckin C; Sacher JR; Wagner F; Stanulla M; Yuan C; Sicinska E; Giannakis M; Ng K; Dow LE; Gutierrez A
Cancer Discov; 2020 Nov; 10(11):1690-1705. PubMed ID: 32703769
[TBL] [Abstract][Full Text] [Related]
6. WNT as a Driver and Dependency in Cancer.
Parsons MJ; Tammela T; Dow LE
Cancer Discov; 2021 Oct; 11(10):2413-2429. PubMed ID: 34518209
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
[TBL] [Abstract][Full Text] [Related]
8. Stat3 is indispensable for damage-induced crypt regeneration but not for Wnt-driven intestinal tumorigenesis.
Oshima H; Kok SY; Nakayama M; Murakami K; Voon DC; Kimura T; Oshima M
FASEB J; 2019 Feb; 33(2):1873-1886. PubMed ID: 30156908
[TBL] [Abstract][Full Text] [Related]
9. APC loss-induced intestinal tumorigenesis in Drosophila: Roles of Ras in Wnt signaling activation and tumor progression.
Wang C; Zhao R; Huang P; Yang F; Quan Z; Xu N; Xi R
Dev Biol; 2013 Jun; 378(2):122-40. PubMed ID: 23570874
[TBL] [Abstract][Full Text] [Related]
10. MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms.
Joosten SPJ; Zeilstra J; van Andel H; Mijnals RC; Zaunbrecher J; Duivenvoorden AAM; van de Wetering M; Clevers H; Spaargaren M; Pals ST
Gastroenterology; 2017 Oct; 153(4):1040-1053.e4. PubMed ID: 28716720
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality between MyD88 loss and mutations in Wnt/β-catenin pathway in intestinal tumor epithelial cells.
Kajino-Sakamoto R; Fujishita T; Taketo MM; Aoki M
Oncogene; 2021 Jan; 40(2):408-420. PubMed ID: 33177648
[TBL] [Abstract][Full Text] [Related]
12. SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium.
Perekatt AO; Shah PP; Cheung S; Jariwala N; Wu A; Gandhi V; Kumar N; Feng Q; Patel N; Chen L; Joshi S; Zhou A; Taketo MM; Xing J; White E; Gao N; Gatza ML; Verzi MP
Cancer Res; 2018 Sep; 78(17):4878-4890. PubMed ID: 29986996
[TBL] [Abstract][Full Text] [Related]
13. SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling.
Oudhoff MJ; Braam MJS; Freeman SA; Wong D; Rattray DG; Wang J; Antignano F; Snyder K; Refaeli I; Hughes MR; McNagny KM; Gold MR; Arrowsmith CH; Sato T; Rossi FMV; Tatlock JH; Owen DR; Brown PJ; Zaph C
Dev Cell; 2016 Apr; 37(1):47-57. PubMed ID: 27046831
[TBL] [Abstract][Full Text] [Related]
14. BRAF
Reischmann N; Andrieux G; Griffin R; Reinheckel T; Boerries M; Brummer T
Oncogene; 2020 Sep; 39(38):6053-6070. PubMed ID: 32792685
[TBL] [Abstract][Full Text] [Related]
15. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
16. Metabolic balance in colorectal cancer is maintained by optimal Wnt signaling levels.
Imkeller K; Ambrosi G; Klemm N; Claveras Cabezudo A; Henkel L; Huber W; Boutros M
Mol Syst Biol; 2022 Aug; 18(8):e10874. PubMed ID: 35904277
[TBL] [Abstract][Full Text] [Related]
17. UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/β-catenin signaling.
Li L; Duan Q; Zeng Z; Zhao J; Lu J; Sun J; Zhang J; Siwko S; Wong J; Shi T; Zhang X; Liu M; Chen J; Li D
Int J Cancer; 2020 Oct; 147(8):2239-2252. PubMed ID: 32372448
[TBL] [Abstract][Full Text] [Related]
18. Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling.
Bonnans C; Flacelière M; Grillet F; Dantec C; Desvignes JP; Pannequin J; Severac D; Dubois E; Bibeau F; Escriou V; Crespy P; Journot L; Hollande F; Joubert D
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3047-52. PubMed ID: 22315403
[TBL] [Abstract][Full Text] [Related]
19. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer.
Yamamoto D; Oshima H; Wang D; Takeda H; Kita K; Lei X; Nakayama M; Murakami K; Ohama T; Takemura H; Toyota M; Suzuki H; Inaki N; Oshima M
J Pathol; 2022 May; 257(1):39-52. PubMed ID: 35040131
[TBL] [Abstract][Full Text] [Related]
20. A hypermorphic epithelial β-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations.
Buchert M; Rohde F; Eissmann M; Tebbutt N; Williams B; Tan CW; Owen A; Hirokawa Y; Gnann A; Orend G; Orner G; Dashwood RH; Heath JK; Ernst M; Janssen KP
Dis Model Mech; 2015 Nov; 8(11):1361-73. PubMed ID: 26398937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
